



Goals of the NIDDK NASH CRN

- Focuses on:
 - Natural history
 - Contributing factors
 - Etiopathogenesis
 - Genetics/epigenetics
 - Environmental contributors/toxins


MAKE

HAPPEN

- Noninvasive imaging and biomarkers
- Complications
- Therapy



Steering Committee with Pediatric Members Shown Steering Committee: Joel Lavine (co-chair), CU ((3553@columbia.edu) Arun Sanyal (co-chair), VCU ((3853@columbia.edu)) Sarah Barlow, BCM ((38670w@bcm.edu)) Naga Chalasani, IU ((nchalasa@uui.edu)) Ed Doo, NIDDK ((3000@nidk.nh).gov) Anna Mae Diehl, DUKE ((anname.diehl@duke.edu)) Saul Karpen, EU ((38470m@bemon.edu)) Kris Kowdley, SMC ((stis.kowdley@ewedish.org)) Rohit Loomba, UCSD ((stio.kowdley@ewedish.org)) Pohit Loomba, UCSD ((stio.kowdley@ewedish.org)) Jean Molleston, IU ((gmenles@uud.edu)) Karen Murray, UW, (anen.murray@eeattechidens.org) Philip Rosenthal, UCSF (((nosenth@neds.ucd.edu)) Jeffrey Schwimmer, UCSD (((schwimmer@uud.edu)) Jeffrey Schwimmer, UCSD (((schwimmer@uud.edu)) Jert Itri, SLU (((setha@guud.edu)) James Tonascia, JHU-DCC ((((nosent@hu.edu))) Peter Whitington, NWU (((()-whitinglou.ed))) Stavra Xanthakos, CiNC ((((stava.anthaos@cochm.org)))




NASH CRN Subject Enrollment Study Total patients		
Study	Total patients	
NAFLD DB	1,503	
PIVENS	247	
TONIC	173	
DB2-Adult	1,754	
DB2-Pediatric	675	
FLINT	283	
CyNCh	169	
All Studies	4,804	
As of 03Oct15		

Ancillary Studies: Summary

- Years of studies: 2004 to present and ongoing
- 106 Ancillary Studies:
 - o 46 Active

 - 31 Completed
 19 Inactive or withdrawn
 10 Disapproved
- 12 Pilot and Feasibility Studies:

 - 8 Completed1 Resubmitted as Ancillary Study3 Inactive or withdrawn
- 38 Presentations and 35 Publications from **Ancillaries**
- 19,740 Biosamples and DNA on 1,474 patients analyzed (2013)



Submitting a Proposal to the Notice of Propo

Ancillary Study Ground Rules

- Involves new data collection
- Funding comes from outside CRN
- Does not use central resources
- Requires Steering Committee liason
- Ancillary and Steering Committees assess scientific/resource merit
- Publications/presentations from AS needs to be approved prior to submission

Publication Category						
Туре	No. Publications	Average Impact Factor				
Clinical Trials	4	21.7				
Epidemiologic	21	9.1				
Genetics	4	13.2				
Histology	7	11.9				
Noninvasive Markers	10	6.5				
Translational	7	10.6				
Total	53	9.3				

STAGES OF TRANSLATIONAL SCIENCE	ACHIEVED and PROPOSED ACTIVITIES
T1: BASIC SCIENCE	Genetics and Systems biology: genetics, microbiome, lipidome, transcriptome, proteome Biomarker discovery: integration of "omics" approaches, Identification of targets: for diagnostics and therapeutics
T2: EARLY TRANSLATION	Partnership with industry: Pharmavite, Intercept, Raptor, Takeda, Echosens, GE, Somalogic Partnerships with other NIH consortia: NURSA, LIPIDMAPS ChiLDREN, TEENLABS Validation of diagnostic targets: Fibroscan, MRI, biosamples Phase 2 A trials: ASBT inhibitor, NHR agonists/antagonists
T3: LATE TRANSLATION	Phase 2b trials: pentoxifylline, vitamin E, obeticholic acid
T4: DISSEMINATION	Inform practice guidelines and remove barriers to drug development by improved diagnostics
T5: ADOPTION	Outcomes and validation of quality of care in NAFLD- standard of care development

Sample of Pediatric Ancillary Studies

- (in progress)

 Hepatic nuclear hormone receptor expression related to NAFLD severity
- The microbiome in development and progression of NAFLD
- Sleep apnea relation to NAFLD histology
- Altered drug metabolism in pediatric NAFLD
- Proteomic biomarkers for NAFLD discrimination
- Hormonal influences on histology



Ancillary Study Ideas for Consideration

- Environmental endocrine disruptors
- Genetic variants explaining ethnic predisposition
- Maternal factors predisposing to NAFLD
- Epigenetic modifications affecting NAFLD
- Novel safe phase I therapeutics
- Sleep apnea interventions on NAFLD
- Lifestyle intervention effects on NAFLD

The NASH CRN is uniquely suited to perform such studies

- Diverse expertise in NASH
- Expertise in metabolism, development
- Pathology consensus and expertise
- Pioneers in liver imaging
- Expertise in gut endocrine function
- Subjects of varying ethnicity/races/geography/ages
- Strong record of collaborative research
- Superb biostatistical support via DCC

Severity of NAFLD in Biopsied Children in Comparison to Adult Enrollees

NAS	Adult (n=3,005)		Pediatric (n=1,136)		Total (n=4,141)	
	No.	(%)	No.	(%)	No.	(%)
0	25	(1)	13	(1)	38	(1)
1	134	(4)	64	(6)	198	(5)
2	444	(15)	157	(14)	601	(15)
3	471	(16)	213	(19)	684	(17)
4	648	(22)	264	(23)	912	(22)
5	542	(18)	226	(20)	768	(19)
6	419	(14)	132	(12)	551	(13)
7	258	(9)	48	(4)	306	(7)
8	64	(2)	19	(2)	83	(2)





